These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 15952868)

  • 1. Applying proteomics in clinical trials: assessing the potential and practical limitations in ovarian cancer.
    Tchabo NE; Liel MS; Kohn EC
    Am J Pharmacogenomics; 2005; 5(3):141-8. PubMed ID: 15952868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis for early detection of ovarian cancer: a realistic approach?
    Stevens EV; Liotta LA; Kohn EC
    Int J Gynecol Cancer; 2003; 13 Suppl 2():133-9. PubMed ID: 14656269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature.
    Posadas EM; Davidson B; Kohn EC
    Curr Opin Oncol; 2004 Sep; 16(5):478-84. PubMed ID: 15314519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of proteomics in ovarian cancer prevention and treatment.
    Meani F; Pecorelli S; Liotta L; Petricoin EF
    Mol Diagn Ther; 2009; 13(5):297-311. PubMed ID: 19791834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian cancer in the proteomics era: diagnosis, prognosis, and therapeutics targets.
    Boyce EA; Kohn EC
    Int J Gynecol Cancer; 2005; 15 Suppl 3():266-73. PubMed ID: 16343243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and challenges in screening for early detection of ovarian cancer.
    Jacobs IJ; Menon U
    Mol Cell Proteomics; 2004 Apr; 3(4):355-66. PubMed ID: 14764655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian cancer: can proteomics give new insights for therapy and diagnosis?
    Toss A; De Matteis E; Rossi E; Casa LD; Iannone A; Federico M; Cortesi L
    Int J Mol Sci; 2013 Apr; 14(4):8271-90. PubMed ID: 23591842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical proteomics and biomarker discovery.
    Johann DJ; McGuigan MD; Patel AR; Tomov S; Ross S; Conrads TP; Veenstra TD; Fishman DA; Whiteley GR; Petricoin EF; Liotta LA
    Ann N Y Acad Sci; 2004 Jun; 1022():295-305. PubMed ID: 15251975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational Research and Plasma Proteomic in Cancer.
    Santini AC; Giovane G; Auletta A; Di Carlo A; Fiorelli A; Cito L; Astarita C; Giordano A; Alfano R; Feola A; Di Domenico M
    J Cell Biochem; 2016 Apr; 117(4):828-35. PubMed ID: 26479787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
    Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma proteomic pattern as biomarkers for ovarian cancer.
    Lin YW; Lin CY; Lai HC; Chiou JY; Chang CC; Yu MH; Chu TY
    Int J Gynecol Cancer; 2006; 16 Suppl 1():139-46. PubMed ID: 16515582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare.
    Bast RC
    Trans Am Clin Climatol Assoc; 2004; 115():233-47; discussion 247-8. PubMed ID: 17060970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer screening: a look at the evidence.
    Fields MM; Chevlen E
    Clin J Oncol Nurs; 2006 Feb; 10(1):77-81. PubMed ID: 16482731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteomics of ovarian cancer: functional insights and clinical applications.
    Elzek MA; Rodland KD
    Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomics analysis for finding serum markers of ovarian cancer.
    Cheng Y; Liu C; Zhang N; Wang S; Zhang Z
    Biomed Res Int; 2014; 2014():179040. PubMed ID: 25250314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HE4 in ovarian cancer: from discovery to clinical application.
    Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
    Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use.
    Duffy MJ; Bonfrer JM; Kulpa J; Rustin GJ; Soletormos G; Torre GC; Tuxen MK; Zwirner M
    Int J Gynecol Cancer; 2005; 15(5):679-91. PubMed ID: 16174214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.